Equities research analysts expect TESARO Inc (NASDAQ:TSRO) to report sales of $88.95 million for the current quarter, Zacks reports. Nine analysts have issued estimates for TESARO’s earnings, with estimates ranging from $76.60 million to $96.40 million. TESARO posted sales of $48.02 million during the same quarter last year, which suggests a positive year-over-year growth rate of 85.2%. The company is scheduled to issue its next earnings report on Tuesday, February 26th.

On average, analysts expect that TESARO will report full year sales of $260.75 million for the current fiscal year, with estimates ranging from $247.90 million to $267.70 million. For the next year, analysts forecast that the company will post sales of $363.18 million, with estimates ranging from $283.10 million to $448.78 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow TESARO.

TESARO (NASDAQ:TSRO) last released its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($2.49) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.62) by $0.13. The business had revenue of $64.40 million during the quarter, compared to analyst estimates of $71.84 million. TESARO had a negative net margin of 295.67% and a negative return on equity of 1,209.72%. The company’s quarterly revenue was down 54.9% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.47) earnings per share.

Several equities analysts recently commented on the stock. Cantor Fitzgerald increased their price objective on shares of TESARO from $57.00 to $68.00 and gave the company a “positive” rating in a research report on Monday, October 22nd. ValuEngine raised shares of TESARO from a “hold” rating to a “buy” rating in a research report on Tuesday. Argus lowered shares of TESARO from a “buy” rating to a “hold” rating in a research report on Wednesday, August 15th. Citigroup decreased their price objective on shares of TESARO from $100.00 to $85.00 and set a “buy” rating for the company in a research report on Wednesday, August 29th. Finally, Bank of America increased their price objective on shares of TESARO from $35.00 to $38.00 and gave the company a “neutral” rating in a research report on Tuesday, September 11th. Eight analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. TESARO presently has a consensus rating of “Buy” and an average price target of $73.25.

A number of institutional investors and hedge funds have recently bought and sold shares of TSRO. Russell Investments Group Ltd. raised its position in shares of TESARO by 54.1% in the first quarter. Russell Investments Group Ltd. now owns 8,498 shares of the biopharmaceutical company’s stock valued at $485,000 after buying an additional 2,985 shares in the last quarter. Legal & General Group Plc raised its position in shares of TESARO by 17.5% in the first quarter. Legal & General Group Plc now owns 43,656 shares of the biopharmaceutical company’s stock valued at $2,495,000 after buying an additional 6,517 shares in the last quarter. Xact Kapitalforvaltning AB raised its position in shares of TESARO by 86.8% in the second quarter. Xact Kapitalforvaltning AB now owns 6,700 shares of the biopharmaceutical company’s stock valued at $298,000 after buying an additional 3,113 shares in the last quarter. Essex Investment Management Co. LLC acquired a new stake in shares of TESARO in the second quarter valued at approximately $733,000. Finally, Fred Alger Management Inc. raised its position in shares of TESARO by 66.6% in the second quarter. Fred Alger Management Inc. now owns 77,870 shares of the biopharmaceutical company’s stock valued at $3,463,000 after buying an additional 31,122 shares in the last quarter.

Shares of TESARO stock traded up $5.72 during midday trading on Thursday, hitting $42.55. The company had a trading volume of 199,924 shares, compared to its average volume of 2,636,409. The firm has a market capitalization of $1.92 billion, a P/E ratio of -4.63 and a beta of 1.35. The company has a quick ratio of 2.83, a current ratio of 3.40 and a debt-to-equity ratio of 3.74. TESARO has a 12-month low of $23.41 and a 12-month high of $88.83.

TESARO Company Profile

Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.

Featured Story: Why is Cost of Capital Important?

Get a free copy of the Zacks research report on TESARO (TSRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.